NeuroVenti (CEO Chan-young Shin and Dong-cheol Seo) announced on the 15th that it participated in the 3rd 'Autism Expo' held at the AT Center in Yangjae-dong from July 12th to 13th.

This event, held every two years, is a nationwide event to increase social awareness of autism disorder and developmental delay and to enable people and their families to lead better lives by communicating with each other and obtaining reliable information. Among Autism-related events, it is by far the largest event.

At this event, NeuroVenti is the only participant to introduce candidates for pharmaceutical treatments, introducing trends and prospects related to the development of the world's first "social disorder treatment" and conducting various participation events such as surveys on inconveniences in life and wish trees for autistic people, providing a place to think about ways to help solve the actual needs and discomfort of autistic people.

Chan-young Shin, CEO of NeuroVenti, has expressed that he is constantly agonizing over "how to resolve their discomfort and improve their quality of life, form a consensus with the general public, and make research and development to restore human natural values a top priority, focusing not only on developing treatments but also on the practical difficulties faced by people and their families.

Close cooperation between companies and support organizations in various fields participating in the Autism Expo is expected in providing integrated solutions for Neuromenti's final goal of diagnosis, treatment, and rehabilitation of developmental disorders. Many autistic disability parties and families who participated in the Autism Expo event show a lot of expectation and interest in Neuromenti's efforts for a healthy life journey, and attention from all walks of life is being paid to the successful implementation of the phase 2 clinical trial, which begins in the second half of this year.